Pierre RABOISSON

• Head of Infection Diseases & Vaccines Medicinal Chemistry.

• Robust track record in RND.
o Result oriented: as head of HCV research, delivered 1 clinical candidate/year (NME), currently 5 compounds under active development.
o Inventor of Simeprevir (TMC435) OLYSIO®, SOVRIAD®, a best in class HCV protease inhibitor recently approved in Japan, Canada and the US; 2.4 B USD sales in 2014 (has been the MedChem project leader for this research program).
o Initiated several projects which reached different stages of research and clinical trials.
o Animal Health: initiated collaborations with Janssen Animal Health on different pathogens, some of them being developed by Elanco.
o Special interest in challenging chemistry, e.g. Nucleotides (over 20 linear steps of synthesis), macrocycles incorporating multiple chiral centers, peptides-peptidomimetics (from antibodies to peptides), and fast follower approaches (rapid value-creation) …

• Evaluation of in licensing opportunities – due diligence.

• Editor and author of “The Practice of Medicinal Chemistry 4th edition”, so called “the bible of Medicinal Chemistry by the scientific community.

• Management commitees:
o Core team member of the Organization Management Committee (OMC).
o Chairman of different JSC’s for key collaborations.
o Permanent member of the ID&V Research & Early Development Management Committee (REDMC), which is the governance body of Infectious disease and vaccine research and development at JNJ.

• Early Development Project team member (input on projects up to end of Ph2a).

• Excellent leadership and managerial skills: Define carrier plans for colleagues and promote based on innovation and results. Assessment of these skills by JNJ Credo survey (yearly survey).

• Good understanding and knowledge of the unmet medical needs in the field of infectious diseases small molecules.